Haruyoshi Tanaka

Haruyoshi Tanaka

Auto-generated profile, based on publicly available information

Haruyoshi Tanaka

Department of Surgery and Science, Faculty of Medicine, Academic Assembly University of Toyama Toyama Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

16 September 2015 in International Journal of Oncology
Verified
Journal Article
Open access
HTHaruyoshi Tanaka
Haruyoshi Tanaka
MKMitsuro Kanda
Mitsuro Kanda
MKMasahiko Koike
Masahiko Koike
NINaoki Iwata
Naoki Iwata
DSDai Shimizu
Dai Shimizu
YKYasuhiro Kodera
Yasuhiro Kodera
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

29 October 2019 in In Vivo
Verified
Journal Article
Open access
PDF file
TMTakashi Miwa
Takashi Miwa
MKMitsuro Kanda
Mitsuro Kanda
SUShinichi Umeda
Shinichi Umeda
HTHaruyoshi Tanaka
Haruyoshi Tanaka
DSDai Shimizu
Dai Shimizu
YKYasuhiro Kodera
Yasuhiro Kodera
Background/Aim: Establishment of mouse xenograft models is necessary for oncological research and depends on the characteristics of the cell lines and the immune system of the host. In this study, we describe the development of mouse xenograft models using human gastric cancer (GC) cell lines. Materials and Methods: MKN1 stably-expressing luciferase (MKN1-Luc), N87, KATO III, MKN45 stably-expressing luciferase (MKN45-Luc), NUGC4, and OCUM-1 human GC cell lines were injected intraperitoneally into mice to establish peritoneal metastasis models. MKN45-Luc were injected into subcutaneously implanted spleen, and MKN1-Luc and MKN45-Luc were injected directly into the portal veins of mice for the establishment of hepatic metastasis models. Results: Peritoneal metastasis was formed after implantation of MKN1-Luc, N87, KATO III, MKN45-Luc, and NUGC4 in nude mice, but not formed in OCUM-1 even in NOD/SCID mice. After intrasplenic injection of MKN45-Luc, we found no hepatic metastasis formation. We identified hepatic metastasis formation after direct injection of MKN45-Luc and MKN1-Luc into the portal veins of NOD/SCID mice. Conclusion: Peritoneal and hepatic metastasis mouse xenograft models were successfully established using several human GC cell lines.

30 July 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
MKMitsuro Kanda
Mitsuro Kanda
DSDai Shimizu
Dai Shimizu
SNShunsuke Nakamura
Shunsuke Nakamura
KSKoichi Sawaki
Koichi Sawaki
SUShinichi Umeda
Shinichi Umeda
YKYasuhiro Kodera
Yasuhiro Kodera

18 July 2023 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
TITakamichi Igarashi
Takamichi Igarashi
MFMina Fukasawa
Mina Fukasawa
TWToru Watanabe
Toru Watanabe
NKNana Kimura
Nana Kimura
AIAyaka Itoh
Ayaka Itoh
Tsutomu FujiiTsutomu Fujii
Tsutomu Fujii
Introduction: The prognosis of pancreatic ductal adenocarcinoma (PDAC) in patients with positive peritoneal washing cytology (CY1) is poor. We aimed to evaluate the results of staging laparoscopy (SL) and treatment efficacy in CY1 patients based on a resectability classification.Methods: We retrospectively reviewed 250 patients with PDAC who underwent SL before the initial treatment between 2017 and 2023 at the University of Toyama.Results: The breakdown of cases by resectability classification was resectable (R):borderline resectable (BR):unresectable locally advanced (UR‐LA) = 131:48:71 cases. The frequency of CY1 increased in proportion to the degree of local progression (R:BR:UR‐LA = 20:23:34%), but the frequencies of liver metastasis or peritoneal dissemination were comparable (R:BR:UR‐LA = 6.9:6.3:8.5%). Most CY1 patients received gemcitabine along with nab‐paclitaxel therapy. The CY‐negative conversion rates (R:BR:UR‐LA = 70:64:52%) and conversion surgery rates (R:BR:UR‐LA = 40:27:9%) were inversely proportional to the degree of local progression.Comparing H0P0CY1 factors for each classification, patients with H0P0CY1 had significantly more pancreatic body or tail carcinoma and tumor size ≥32 mm in R patients, whereas in BR patients, duke pancreatic monoclonal antigen type 2 (DUPAN‐2) ≥ 230 U/mL was a significant factor. In contrast, no significant factors were observed in UR‐LA patients.Conclusion: The CY1 rates, CY‐negative conversion rates, and conversion surgery rates varied according to local progression. In the case of R and BR, SL could be considered in patients with pancreatic body or tail carcinoma, large tumor size, or high DUPAN‐2 level. In UR‐LA, SL might be considered for all patients.

14 April 2021 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
HTHaruyoshi Tanaka
Haruyoshi Tanaka
MKMitsuro Kanda
Mitsuro Kanda
TMTakashi Miwa
Takashi Miwa
SUShinichi Umeda
Shinichi Umeda
KSKoichi Sawaki
Koichi Sawaki
YKYasuhiro Kodera
Yasuhiro Kodera